Get the Stockscreener App
101.38
1.28%
1.28
After Hours:
101.38
Neurocrine Biosciences Inc stock is traded at $101.38, with a volume of 1.93M.
It is up +1.28% in the last 24 hours and down -9.08% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$100.10
Open:
$99.35
24h Volume:
1.93M
Relative Volume:
1.35
Market Cap:
$9.39B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
27.18
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
+11.75%
1M Performance:
-9.08%
6M Performance:
-14.42%
1Y Performance:
-23.91%
1-Day Range:
$99.35
$102.05
1-Week Range:
$88.35
$102.05
52-Week Range:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
101.38 | 9.39B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Do Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Warrant Your Attention? - simplywall.st
(NBIX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (NBIX) - Seeking Alpha
Needham Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish - Benzinga
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Needham Upgrades Neurocrine Biosciences (NBIX) - Nasdaq
Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com
RBC Capital Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq
RBC Capital lifts Neurocrine Bio. stock rating to Outperform By Investing.com - Investing.com Canada
Neurocrine Earnings Preview: Leading Neuroscience Firm to Reveal Q1 2025 Performance - Stock Titan
RBC Capital Upgrades Neurocrine Biosciences (NBIX) - Nasdaq
Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says - MarketScreener
Neurocrine stock upgraded at RBC Capital Markets (NBIX:NASDAQ) - Seeking Alpha
RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug - TradingView
RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138 - MarketScreener
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN
Tourette Syndrome Treatment Market Generated Opportunities, - openPR.com
Neurocrine Biosciences names Sanjay Keswani as chief medical officer - MSN
Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com Canada
NBIXNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - ADVFN
Ex-Dyne team members reconvene at Crescent - biocentury.com
Neurocrine Biosciences Appoints New Chief Medical Officer - MarketScreener
UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com Canada
Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medi - GuruFocus
Neurocrine Biosciences names new Chief Medical Officer - Investing.com India
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma
Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - MarketScreener
Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider
UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - PR Newswire
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener
Neurocrine Biosci stock hits 52-week low at $105.17 By Investing.com - Investing.com South Africa
Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com
Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail
Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences executive sells shares worth $266,024 - MSN
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia - PR Newswire
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan
Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga
Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView
Tardive Dyskinesia Treatment Market Expands with New Drug - openPR
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo
Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter
Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '25 |
Sale |
116.78 |
1,551 |
181,129 |
19,544 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Option Exercise |
0.00 |
10,979 |
0 |
527,221 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Sale |
116.69 |
5,844 |
681,914 |
521,618 |
| SHERWIN STEPHEN A | Director |
Feb 13 '25 |
Sale |
116.69 |
13,831 |
1,613,923 |
10,673 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,605 |
0 |
36,140 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Sale |
116.85 |
1,718 |
200,742 |
34,252 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 14 '25 |
Sale |
115.04 |
500 |
57,521 |
35,640 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
5,407 |
0 |
19,536 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Sale |
116.79 |
2,879 |
336,239 |
16,846 |
| Lippoldt Darin | Chief Legal Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,100 |
0 |
44,491 |
2.30%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):